Textile · Founded 2012 · www.cpsshapersltd.com · NSE · ISIN INE0QBU01012
No Notes Added Yet
1. Business Overview
CPS Shapers Ltd. is an Indian company primarily engaged in the manufacturing and selling of shapewear, activewear, and other related apparel products for men and women. The company operates under the brand name "Dermawear". Its core business model involves designing, producing, and distributing its products through a multi-channel approach, including a direct-to-consumer (D2C) model via its website, a pan-India network of distributors and retailers, and online marketplaces. It makes money by selling its branded apparel products directly to consumers and through its distribution network.
2. Key Segments / Revenue Mix
While specific revenue contribution percentages for each segment are not readily available in public domain, CPS Shapers' primary product categories include:
Shapewear: A wide range of products for men and women aimed at body shaping and contouring.
Activewear: Apparel designed for physical activities, including sportswear, leggings, and T-shirts.
Thermals/Innerwear: Products designed for warmth and comfort, often including specialized innerwear.
Other Apparel: May include hosiery, vests, and other casual wear.
Sales channels include offline retail (multi-brand outlets, large format stores), online marketplaces, and its own e-commerce platform.
3. Industry & Positioning
CPS Shapers operates in the Indian textile and apparel industry, specifically within the niche but growing segments of shapewear and activewear. This industry is characterized by increasing urbanization, rising disposable incomes, and a growing emphasis on health, wellness, and body aesthetics. The market is fragmented with both organized and unorganized players. CPS Shapers, with its "Dermawear" brand, positions itself as an established player known for quality and specialized products within the premium to mid-segment. It competes with other domestic and international brands in shapewear (e.g., Zivame, Clovia, Amante, Marks & Spencer) and activewear (e.g., Decathlon, Nike, Adidas, Puma, various domestic brands).
4. Competitive Advantage (Moat)
CPS Shapers possesses several potential competitive advantages:
Established Brand (Dermawear): "Dermawear" has a presence in the Indian market, building trust and recognition among consumers for its specialized shapewear and activewear products.
Distribution Network: A pan-India offline distribution network, complemented by an online presence, provides significant reach.
Product Specialization: A focus on niche segments like shapewear and functional activewear allows for expertise and product differentiation.
Manufacturing Capabilities: In-house manufacturing provides control over quality, production costs, and lead times.
5. Growth Drivers
Growing Health & Wellness Trends: Increasing consumer focus on fitness, healthy lifestyles, and body image drives demand for activewear and shapewear.
Rising Disposable Incomes & Urbanization: Increases discretionary spending on specialized apparel, particularly in urban and semi-urban areas.
E-commerce Penetration: Further growth in online retail allows the company to expand its reach to a wider customer base at lower distribution costs.
Organized Retail Growth: Expansion into more organized retail chains and large format stores provides additional sales avenues.
Women's Empowerment & Changing Lifestyles: Increasing participation of women in the workforce and their changing fashion preferences contribute to demand for modern innerwear and activewear.
Product Diversification: Expansion into new, related product categories or geographical markets could fuel growth.
6. Risks
Intense Competition: The apparel market is highly competitive with numerous domestic and international brands, including fast fashion players, constantly vying for market share.
Changing Fashion Trends: Apparel is highly susceptible to rapid changes in fashion and consumer preferences, requiring continuous product innovation and inventory management.
Raw Material Price Volatility: Fluctuations in the prices of raw materials (e.g., fabric, elastic) can impact production costs and profit margins.
Supply Chain Disruptions: Reliance on specific suppliers or manufacturing processes can lead to risks from geopolitical events, natural disasters, or logistics issues.
Economic Downturn: A slowdown in the economy could reduce discretionary spending on apparel, impacting sales.
Inventory Management: Inefficient inventory management can lead to obsolescence, markdowns, and reduced profitability.
7. Management & Ownership
CPS Shapers Ltd. is promoted by the Patel family. Mr. Rameshkumar Garachbhai Patel is the Chairman and Managing Director, with Mr. Jayeshkumar Garachbhai Patel serving as a Whole Time Director. The management team typically brings experience in the textile and apparel sector. As a listed entity, it would have public shareholders, but the promoters usually retain a significant ownership stake, indicating strong commitment to the company's long-term vision.
8. Outlook
CPS Shapers Ltd. operates in attractive segments of the Indian apparel market, specifically shapewear and activewear, which are benefiting from strong tailwinds like increasing health consciousness and rising disposable incomes. The "Dermawear" brand has an established presence and a multi-channel distribution strategy that positions it well to capture growth. The company's in-house manufacturing capabilities offer some control over quality and costs.
However, the company faces significant competition from both domestic and international brands, and is exposed to risks associated with rapidly changing fashion trends and raw material price volatility. Its ability to continuously innovate, manage inventory efficiently, and effectively scale its distribution, especially in the competitive online space, will be crucial. While the market offers substantial growth opportunities, execution and sustained brand appeal will determine its long-term success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 14 | 27 | 37 | 36 | 31 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 14 | 27 | 37 | 36 | 31 | |
| Total Expenditure | 13 | 24 | 32 | 33 | 29 | |
| Operating Profit | 2 | 2 | 5 | 3 | 2 | |
| Interest | 1 | 1 | 1 | 2 | 1 | |
| Depreciation | 0 | 0 | 1 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 0 | 1 | 3 | 1 | 0 | |
| Provision for Tax | -0 | -0 | 1 | 0 | -0 | |
| Profit After Tax | 0 | 2 | 2 | 1 | 0 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 2 | 2 | 1 | 0 | |
| Adjusted Earnings Per Share | 2.5 | 10.5 | 16.4 | 3.5 | 0.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -14% | 5% | 0% | 0% |
| Operating Profit CAGR | -33% | 0% | 0% | 0% |
| PAT CAGR | -100% | -100% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 23% | NA% | NA% | NA% |
| ROE Average | 1% | 162% | 97% | 97% |
| ROCE Average | 5% | 21% | 22% | 22% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | -2 | -1 | 2 | 12 | 17 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 4 | 5 | 6 | 2 | 2 |
| Other Non-Current Liabilities | 0 | -0 | 1 | 0 | 0 |
| Total Current Liabilities | 9 | 8 | 10 | 11 | 10 |
| Total Liabilities | 11 | 12 | 17 | 25 | 29 |
| Fixed Assets | 2 | 3 | 4 | 5 | 6 |
| Other Non-Current Assets | 0 | 0 | 0 | 1 | 0 |
| Total Current Assets | 9 | 9 | 14 | 19 | 23 |
| Total Assets | 11 | 12 | 17 | 25 | 29 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 2 |
| Cash Flow from Operating Activities | 1 | 2 | 1 | -3 | -3 |
| Cash Flow from Investing Activities | -0 | -1 | -1 | -3 | -2 |
| Cash Flow from Financing Activities | -1 | -1 | 0 | 7 | 3 |
| Net Cash Inflow / Outflow | 0 | -0 | -0 | 2 | -2 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 2 | 0 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.54 | 10.47 | 16.41 | 3.52 | 0.76 |
| CEPS(Rs) | 4.59 | 12.51 | 19.85 | 6.63 | 4.55 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -15.2 | -4.73 | 11.67 | 57.09 | 76.57 |
| Core EBITDA Margin(%) | 11.88 | 8.96 | 13.07 | 8.71 | 6.17 |
| EBIT Margin(%) | 9.91 | 7.83 | 12.07 | 7.33 | 3.61 |
| Pre Tax Margin(%) | 2.55 | 4.62 | 9.38 | 3.09 | 0.21 |
| PAT Margin (%) | 2.64 | 5.89 | 6.68 | 2.05 | 0.54 |
| Cash Profit Margin (%) | 4.79 | 7.03 | 8.09 | 3.87 | 3.26 |
| ROA(%) | 3.52 | 13.66 | 16.59 | 3.45 | 0.62 |
| ROE(%) | 0 | 0 | 472.59 | 10.76 | 1.16 |
| ROCE(%) | 19.83 | 26.38 | 42.72 | 15.83 | 4.83 |
| Receivable days | 56.23 | 33.17 | 25.87 | 30.48 | 54.23 |
| Inventory Days | 139.89 | 75.36 | 72.46 | 102.12 | 137.13 |
| Payable days | 207.02 | 86.77 | 81.86 | 88.78 | 84.94 |
| PER(x) | 0 | 0 | 0 | 98.05 | 705.43 |
| Price/Book(x) | 0 | 0 | 0 | 6.04 | 6.99 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.67 | 0.36 | 0.29 | 2.22 | 4.09 |
| EV/Core EBITDA(x) | 5.59 | 4.03 | 2.16 | 24.28 | 64.63 |
| Net Sales Growth(%) | 0 | 85.42 | 37.97 | -2.15 | -14.34 |
| EBIT Growth(%) | 0 | 46.5 | 112.56 | -40.6 | -57.77 |
| PAT Growth(%) | 0 | 312.77 | 56.69 | -69.98 | -77.3 |
| EPS Growth(%) | 0 | 312.77 | 56.69 | -78.55 | -78.45 |
| Debt/Equity(x) | -4.16 | -13.18 | 5.94 | 0.77 | 0.47 |
| Current Ratio(x) | 0.95 | 1.11 | 1.44 | 1.78 | 2.25 |
| Quick Ratio(x) | 0.34 | 0.44 | 0.49 | 0.75 | 1.05 |
| Interest Cover(x) | 1.35 | 2.44 | 4.49 | 1.73 | 1.06 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.13 | 0.07 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 71.29 | 71.29 | 71.29 | 67.7 | 67.7 | 65.71 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 2.77 | 3.06 | 3.06 | 2.12 | 0 | 0 |
| Public | 25.94 | 25.66 | 25.66 | 30.18 | 32.3 | 34.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
| Public | 0.05 | 0.05 | 0.05 | 0.07 | 0.07 | 0.08 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.21 | 0.21 | 0.21 | 0.22 | 0.22 | 0.23 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 71.29 | 71.29 | 71.29 | 67.7 | 67.7 | 65.71 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 2.77 | 3.06 | 3.06 | 2.12 | 0 | 0 |
| Public | 28.71 | 28.71 | 28.71 | 32.3 | 32.3 | 34.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
| Public | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.21 | 0.21 | 0.21 | 0.22 | 0.22 | 0.23 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -14% | +5% | — | — |
| Operating Profit CAGR | -33% | 0% | — | — |
| PAT CAGR | -100% | -100% | — | — |
| Share Price CAGR | +23% | — | — | — |
| ROE Average | +1% | +162% | +97% | +97% |
| ROCE Average | +5% | +21% | +22% | +22% |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.